Send Away Test for Oncotype DX Breast Recurrence Score
In plain English
The notice doesn't say
The notice as published
Provision of Oncotype DX Breast Recurrence Score testing which addresses the issue of overtreatment with chemotherapy, particularly for patients with lymph nod-positive breast cancer. This contract is to commission Exact Science to provide Oncotype DX Breast Recurrence Score which is a genomic assay that provides a personalised insight into an individual patients breast cancer biology. <br/>This contract has been awarded under Direct Award A <br/>The lifetime value of this contract is £214,650 <br/>The contract is in place from 1st July 2025 until 30th June 2026